论文部分内容阅读
目的观察利拉鲁肽治疗超重2型糖尿病患者的疗效及对胰岛素抵抗的影响。方法选取94例超重2型糖尿病患者,随机分为观察组和对照组各47例。对照组停用以前的降糖方案,予门冬胰岛素注射液联合甘精胰岛素注射液降糖。观察组在对照组治疗的基础上加用利拉鲁肽注射液降糖。结果两组治疗前在FBG、2h PG、Hb A1C比较,无显著差异(P>0.05),两组治疗后在FBG、2h PG、Hb A1C比较,观察组优于对照组(P<0.05)。两组治疗前在BMI、腰围、胰岛素抵抗指数及胰岛素敏感指数比较,无显著差异(P>0.05),两组治疗后在BMI、腰围、胰岛素抵抗指数及胰岛素敏感指数比较,观察组优于对照组(P<0.05)。结论利拉鲁肽可降低超重2型糖尿病患者的体重,改善胰岛素抵抗,疗效显著。
Objective To observe the efficacy and the effect of liraglutide on insulin resistance in patients with overweight type 2 diabetes mellitus. Methods 94 patients with overweight type 2 diabetes mellitus were randomly divided into observation group and control group, 47 cases each. The control group to disable the previous hypoglycemic regimen, aspart insulin injection combined with insulin glargine hypoglycemic. Observation group in the control group based on the addition of liraglutide injection hypoglycemic. Results There was no significant difference in FBG, 2h PG and Hb A1C between the two groups before treatment (P> 0.05). The FBG, 2h PG and Hb A1C after treatment in both groups were better than those in the control group (P <0.05). There were no significant differences in BMI, waist circumference, insulin resistance index and insulin sensitivity index between the two groups before treatment (P> 0.05). The BMI, waist circumference, insulin resistance index and insulin sensitivity index of the two groups were better than those of the control group Group (P <0.05). Conclusion Liraglutide can reduce the body weight of overweight type 2 diabetic patients and improve insulin resistance with a significant effect.